Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.91
+0.17 (1.95%)
At close: Sep 26, 2025, 4:00 PM EDT
8.89
-0.02 (-0.22%)
After-hours: Sep 26, 2025, 7:00 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Medical Countermeasures Products | 509.80M | Log In | Log In | Log In | Log In | Upgrade |
Medical Countermeasures Products Growth | 14.00% | Log In | Log In | Log In | Log In | Upgrade |
Commercial Products | 398.90M | Log In | Log In | Log In | Log In | Upgrade |
Commercial Products Growth | -19.79% | Log In | Log In | Log In | Log In | Upgrade |
Services | 104.90M | Log In | Log In | Log In | Log In | Upgrade |
Services Growth | 33.63% | Log In | Log In | Log In | Log In | Upgrade |
Reconciling Items | 30.00M | Log In | Log In | Log In | Log In | Upgrade |
Reconciling Items Growth | 14.07% | Log In | Log In | Log In | Log In | Upgrade |
Government - Medical Countermeasures and Commercial Product | - | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing Services | - | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing Services Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Nasal Naloxone Products | - | Log In | Log In | Log In | Log In | Upgrade |
Nasal Naloxone Products Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing - Services | - | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing - Leases | - | Log In | Log In | Log In | Log In | Upgrade |
Anthrax Vaccines | - | Log In | Log In | Log In | Log In | Upgrade |
Anthrax Vaccines Growth | - | Log In | Log In | Log In | Log In | Upgrade |
ACAM2000 | - | Log In | Log In | Log In | Log In | Upgrade |
ACAM2000 Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Other | 80.60M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -63.01% | Log In | Log In | Log In | Log In | Upgrade |
United States | 822.60M | Log In | Log In | Log In | Log In | Upgrade |
United States Growth | 35.47% | Log In | Log In | Log In | Log In | Upgrade |
Canada | 140.40M | Log In | Log In | Log In | Log In | Upgrade |
Canada Growth | -37.38% | Log In | Log In | Log In | Log In | Upgrade |
Other | 80.60M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -63.01% | Log In | Log In | Log In | Log In | Upgrade |